· investment-strategies · 1 min read
Canaan Partners Leads Vedana Therapeutics Series A
Canaan Partners led a Series A for Vedana Therapeutics, extending the firm’s healthcare franchise as it deploys its $850M Fund XIII.
Canaan Partners led a Series A for Vedana Therapeutics in June 2026, extending the firm’s healthcare franchise as it actively deploys its $850M Fund XIII.
Key facts
- Lead investor: Canaan Partners
- Company: Vedana Therapeutics (biopharma)
- Round: Series A
- Date: June 2026
- Fund: Canaan XIII ($850M, April 2023); ~$6.8B total AUM
- Track record: 73 IPOs and 152 M&As across 35+ years
Why this matters
Vedana reflects Canaan Partners’ long-standing healthcare practice (Day One Biopharmaceuticals, IDEAYA, Synthekine) alongside its technology investing, all from the same multi-generation platform.
Sources
- Canaan Partners portfolio (Caplight): https://www.caplight.com/investor/canaan
- Canaan XIII $850M announcement: https://canaan.com/latest/announcing-canaan-xiii
Share: